APLIF News and Press, Appili Therapeutics Inc From 11/13/20

Appili Therapeutics (APLIF): F1H GAAP EPS of -$0.09.Cash and short-term investments of $22.9M.Press Release For further details see: Appili Therapeutics reports F1H results

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the second quarter of its fiscal year 2021, which ended September 30, 2020. &#...

Consortium brings together world-class and globally coordinated clinical development, commercialization, cGMP manufacturing, and logistics expertise to accelerate the deployment and availability of Avigan® tablets for the potential treatment and prevention of COVID-19 A...

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company developing anti-infective drug candidates, today announced that it has recruited Don Cilla, PharmD, MBA, to serve as the Company’s new Chief Dev...

Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, announced today that Appili’s CEO Dr. Armand Balboni will be presenting at the first-ever Life Sc...

Appili Therapeutics ([[APLIF]]) has entered into an agreement with Ology Biosciences, under which Ology will manufacture ATI-1701, a novel live attenuated tularemia vaccine candidate.The U.S. Department of Defense has awarded Ology Bioservices $6.3M for ATI-1701 manufacturing and development ...

Agreement with Ology Bioservices and a $6.3MM DTRA contract enable next stage of manufacturing and development for world’s first vaccine to prevent F. tularensis , a potential biological weapons threat Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Compan...

The first participants have been dosed in a Phase 2 clinical trial evaluating Appili Therapeutics' (APLIF) favipiravir as a preventative measure against COVID-19 outbreaks in long-term care ((LTC)) facilities.The trial will include elderly subjects with comorbidities at 16 LTC centers and fro...

CONTROL trial is part of Appili’s unique approach to evaluating favipiravir in early-stage disease in the community setting for those most vulnerable to COVID-19, including the elderly, those with significant comorbidities, and frontline workers Researchers plan to enro...

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that its common shares will commence trading on the Toronto Stock Exchange (TSX) as of the opening of trading on Wednesday, Septem...